Diabetes Center, Department of Internal Medicine, Section of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.
J Diabetes. 2012 Jun;4(2):181-5. doi: 10.1111/j.1753-0407.2011.00168.x.
Bone metabolism is a dynamic process that is influenced by food ingestion. Endogenous incretins have been shown to be important regulators of bone turnover. The aim of the present study was to assess whether a dipeptidylpeptidase (DPP)-4 inhibitor affects markers of bone resorption and calcium homeostasis.
The present study was a single-center, double blind, randomized clinical trail. Fifty-nine drug-naïve patients with type 2 diabetes (T2D) were randomized to either 1 year treatment with the DPP-4 inhibitor vildagliptin (100 mg, once daily; n = 29) or placebo (n = 30). Patients received a standardized breakfast after measurement of serum concentrations of cross-linked C-terminal telopeptide (s-CTx), a bone resorption marker influenced by food intake, before and after 50 weeks treatment.
Vildagliptin did not change postprandial s-CTx concentrations compared with pretreatment levels (between-group ratio 1.15 ± 0.17; P = 0.320). Fasting serum alkaline phosphatase, calcium, and phosphate were also unaffected y 1 year treatment with vildagliptin.
Treatment with vildagliptin for 1 year was not associated with changes in markers of bone resorption and calcium homeostasis in drug-naïve patients with T2D and mild hyperglycemia.
骨骼代谢是一个受食物摄入影响的动态过程。内源性肠降血糖素已被证明是骨转换的重要调节因子。本研究旨在评估二肽基肽酶-4（DPP-4）抑制剂是否会影响骨吸收和钙稳态的标志物。
本研究为单中心、双盲、随机临床试验。59 例初治 2 型糖尿病（T2D）患者随机分为 1 年的 DPP-4 抑制剂维格列汀（100mg，每日 1 次；n=29）或安慰剂（n=30）治疗组。在 50 周治疗前后，患者在测量血清交联 C 端肽（s-CTX）浓度后，接受标准化早餐，s-CTX 是一种受食物摄入影响的骨吸收标志物。
与治疗前相比，维格列汀治疗后餐后 s-CTX 浓度没有变化（组间比值 1.15±0.17；P=0.320）。1 年维格列汀治疗也未影响空腹血清碱性磷酸酶、钙和磷。
在初治、伴有轻度高血糖的 T2D 患者中，1 年的维格列汀治疗与骨吸收标志物和钙稳态标志物的变化无关。
